

# Chronic GVHD

---

- If you are on the call, you or someone else you love is likely experiencing chronic GVHD
- Please check these out:

<https://www.nbmtlink.org/chronic-graft-versus-host-disease-education-and-support-webinar/>

Mary Flowers



Annie Im



<https://www.nbmtlink.org/webinars-podcasts/webinar-chronic-graft-vs-host-disease-webinar/>


# Outline

---

- Our goal as providers and researchers in this field is to educate
- We want to improve your lives by providing care AND to let you know more about chronic GVHD and what we're trying to do behind the scenes about it.
  - ✓ Immune effects of donor (allogeneic) stem cell transplant
  - ✓ Immune toxicity (graft versus host disease)
  - ✓ Individual/"personalized" treatments
  - ✓ It's an exciting hopeful time!!

*I have a clinical trial with an inhibitor and that is a conflict of interest. Nothing I'm about to say is meant to guide treatment or persuade you to do anything. Go to your provider for advice!*

# Allogeneic Stem Cell Transplantation (HCT)






Ocular sicca




Oral ulcers





Nail dystrophy




Skin sclerosis




Deep sclerosis



Bronchiolitis obliterans



Loss of bile ducts



Fasciitis



Skin ulcers

Spectrum of manifestations in chronic GVHD  
*Courtesy of Steve Pavletic MD, NCI*



ELSEVIER

## Biology of Blood and Marrow Transplantation

journal homepage: [www.bbmt.org](http://www.bbmt.org)

ASBMT™  
American Society for Blood and Marrow Transplantation

Report

### National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report



Paul A. Carpenter<sup>1,\*</sup>, Carrie L. Kitko<sup>2</sup>, Sharon Elad<sup>3</sup>, Mary E.D. Flowers<sup>1</sup>, Juan C. Gea-Banacloche<sup>4</sup>, Jörg P. Halter<sup>5</sup>, Flora Hoodin<sup>6</sup>, Laura Johnston<sup>7</sup>, Anita Lawitschka<sup>8</sup>, George B. McDonald<sup>1</sup>, Anthony W. Pipari<sup>9</sup>, Bipin N. Savani<sup>10</sup>, Kirk R. Schultz<sup>11</sup>, Sean R. Smith<sup>12</sup>, Karen L. Syrjala<sup>1</sup>, Nathaniel Treister<sup>13</sup>, Georgia B. Vogelsang<sup>14</sup>, Kirsten M. Williams<sup>4</sup>, Steven Z. Pavletic<sup>4</sup>, Paul J. Martin<sup>1</sup>, Stephanie J. Lee<sup>1</sup>, Daniel R. Couriel<sup>2</sup>

NATIONAL INSTITUTES OF HEALTH

BMT LATE EFFECTS INITIATIVE

***IMMUNE DYSREGULATION AND  
PATHOBIOLOGY WORKING GROUP***



ELSEVIER

Biology of Blood and  
Marrow Transplantation

journal homepage: [www.bbmt.org](http://www.bbmt.org)



February 19, 2016

Honolulu, hi

National Institutes of Health Hematopoietic Cell  
Transplantation Late Effects Initiative: The Immune  
Dysregulation and Pathobiology Working Group Report

Juan Gea-Banacloche <sup>1,\*</sup>, Krishna V. Komanduri <sup>2</sup>, Paul Carpenter <sup>3,4</sup>, Sophie Paczesny <sup>5</sup>,  
Stefanie Sarantopoulos <sup>6</sup>, Jo-Anne Young <sup>7</sup>, Nahed El Kassar <sup>8</sup>, Robert Q. Le <sup>9</sup>, Kirk R. Schultz <sup>10</sup>,  
Linda M. Griffith <sup>11</sup>, Bipin N. Savani <sup>12</sup>, John R. Wingard <sup>13,14</sup>

BMT Late Effects  
NIH Consortium 



# Consensus Groups & Consortia

---


- NIH Consensus Criteria, 2005, 2015
- NIH Consensus on Immune Deficiency after HCT, 2016
- Chronic GVHD consortium member
- Chronic GVHD natural history study at NCI, collaborate w/ Steve Pavletic

# cGVHD Team at Duke!

Rambi Cardones, MD




Barbara Alexander, MD Jen (Horan) Saullo



Diana Cardona, MD



Keith Sullivan, MD




Ankoor Shah, MD



Victor Perez, MD



Scott Palmer MD



Jamie Todd MD





**Duke University**  
School of Medicine



**DUKE GVHD**

Multi-disciplinary

Research Care


Team




**Duke Cancer Institute**

# Studies Using Patient Samples have advance our Understanding of cGVHD


---




Leukapheresis →



Blood draws




# Schematic overview of the cellular and molecular mediators, known and implicated, contributing to the continuum of aGVHD and cGVHD pathology.



Kelli P. A. MacDonald et al. Blood 2017;129:13-21

# Targeted Treatment is Being Developed in Hopes of Preventing both cGVHD and Cancer Development


---



**Commentary by Daniel H. Fowler, and Steven Z. Pavletic**  
**Blood 2015;125:3974-3975**

©2015 by American Society of Hematology


# Mechanistic interventions for the prevention or treatment of chronic GVHD.



Corey S. Cutler et al. Blood 2017;129:22-29



## How to we decide if you're responding to treatment and what to do next?



**NIH global severity assessments to determine need for intervention in patients with ongoing cGVHD.**

**Our approach to patients seen in our multidisciplinary clinic for ongoing refractory cGVHD entails assessment of global severity score**

Stefanie Sarantopoulos et al. *Blood* 2019;133:1191-1200

# Chronic Graft-versus-Host Disease: A Long Road Ahead



Sarah Anand<sup>1</sup>, Stefanie Sarantopoulos<sup>2,\*</sup>

<sup>1</sup> Adult Blood and Marrow Transplantation, Division of Hematology and Oncology, Department of Medicine, University of Michigan, Ann Arbor, Michigan

<sup>2</sup> Duke Cancer Institute, Division of Hematological Malignancies and Cellular Therapy, Department of Medicine, Duke University, Durham, North Carolina

National Cancer Institute  
Consensus Project  
Steve Pavletic

<https://www.asbmt.org/practice-resources/nih-chronic-gvhd-consensus-project>



*Stephanie Lee*  
*U of Wash, Fred Hutch*

MEREDITH A.  
*Cowden*  
FOUNDATION

